QLT Liable For Unfair Trade In Visudyne Litigation

Law360, New York (November 7, 2006, 12:00 AM EST) -- A federal jury has found biopharmaceutical company QLT Inc. liable for unjust enrichment and unfair trade practices but not liable for trade secret misappropriation in a countersuit brought by the Massachusetts Ear and Eye Infirmary over eye treatment Visudyne.

The jury handed down the decision on Monday, awarding MEEI a royalty of 3.01% on the net sales of Visudyne. Net sales of the treatment from its launch in 2000 to the end of the past Sept. totaled $2.2 billion worldwide, according to QLT, but it is...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.